Sign in Subscribe
Tuberculosis

Breakthrough in Tuberculosis Research: New Vaccine Development Shows Promising Results

Strategic Insights

— 2 min read

Researchers at the Texas Biomedical Research Institute have made significant strides in developing a new vaccine against Mycobacterium tuberculosis, the pathogen responsible for tuberculosis (TB). According to a recent study published in Jci Insight, the new vaccine has shown impressive results in protecting nonhuman primates against lethal TB challenge. The study's lead author, Caden W. Munson, notes that the vaccine has been found to be safe and effective in inducing strong cellular immune responses in the lung, which is a key correlate of protection from TB.

Key Takeaways:

  • The new vaccine, developed by the Texas Biomedical Research Institute, has been shown to protect 2 species of nonhuman primates against lethal TB challenge, indicating its potential as a effective vaccine against TB.
  • The vaccine uses a mutant strain of Mycobacterium tuberculosis, called MtbDsigH, which has been designed to invoke superior T and B cell responses in the lungs through superior antigen presentation and interferon conditioning.
  • The vaccine has been found to be safe and effective in inducing strong cellular immune responses in the lung, which is a key correlate of protection from TB.
  • The study's lead author, Caden W. Munson, notes that the vaccine has the potential to be used in combination with other TB therapies to significantly reduce TB incidence and mortality by 2035, as set out by the WHO End TB Strategy.
  • Additional authors of the study include Garima Arora, Mushtaq Ahmed, Vinay Shivanna, Annu Devi, Venkata Sr Devireddy, Basil Antony, Shannan Hall-Ursone, Olga D. Gonzalez, Edward J. Dick, Chinnaswamy Jagannath, Xavier Alvarez, Smriti Mehra, Shabaana A. Khader, and Dhiraj K. Singh.

Statistics:

  • By 2035, there is a desperate need for improved TB therapies and a more effective vaccine against the deadly pathogen Mycobacterium tuberculosis.
  • The WHO End TB Strategy aims to reduce TB incidence and mortality by 2035.
  • 2 species of nonhuman primates were used in the study to test the efficacy of the new vaccine.
  • The vaccine was found to induce strong cellular immune responses in the lung, which is a key correlate of protection from TB.
  • The vaccine was found to be safe and effective in a preclinical study in the rhesus macaque model of aerosol infection and SIV/HIV coinfection.

Sources:

  • Development and preclinical evaluation of next-generation DsigH-based live candidate vaccines. Jci Insight, 2025;10(19).
  • Caden W. Munson, Texas Biomedical Research Institute, San Antonio, Texas, United States.
  • Jci Insight, Amer Soc Clinical Investigation Inc, 2015 Manchester Rd, Ann Arbor, MI 48104, USA.

Read more